StressCovidV1, Main, Exploration, bibRecord, 001504

[Bisphosphonate treatment of osteoporosis and other skeletal diseases].

Identifieur interne : 001504 ( Main/Exploration ); précédent : 001503; suivant : 001505

[Bisphosphonate treatment of osteoporosis and other skeletal diseases].

Auteurs : Unni Syversen [Norvège] ; Johan I. Halse

Source :

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke [ 0807-7096 ] ; 2011.

RBID : pubmed:21304573

Descripteurs français

KwdFr :
- Agents de maintien de la densité osseuse (administration et posologie), Agents de maintien de la densité osseuse (effets indésirables), Agents de maintien de la densité osseuse (pharmacocinétique), Agents de maintien de la densité osseuse (usage thérapeutique), Analyse coût-bénéfice, Diphosphonates (administration et posologie), Diphosphonates (effets indésirables), Diphosphonates (pharmacocinétique), Diphosphonates (usage thérapeutique), Fractures de fatigue (traitement médicamenteux), Humains, Maladies osseuses (traitement médicamenteux), Ostéoporose (traitement médicamenteux), Résultat thérapeutique.
MESH :
- administration et posologie : Agents de maintien de la densité osseuse, Diphosphonates.
- effets indésirables : Agents de maintien de la densité osseuse, Diphosphonates.
- pharmacocinétique : Agents de maintien de la densité osseuse, Diphosphonates.
- traitement médicamenteux : Fractures de fatigue, Maladies osseuses, Ostéoporose.
- usage thérapeutique : Agents de maintien de la densité osseuse, Diphosphonates.
- Analyse coût-bénéfice, Humains, Résultat thérapeutique.

English descriptors

KwdEn :
- Bone Density Conservation Agents (administration & dosage), Bone Density Conservation Agents (adverse effects), Bone Density Conservation Agents (pharmacokinetics), Bone Density Conservation Agents (therapeutic use), Bone Diseases (drug therapy), Cost-Benefit Analysis, Diphosphonates (administration & dosage), Diphosphonates (adverse effects), Diphosphonates (pharmacokinetics), Diphosphonates (therapeutic use), Fractures, Stress (drug therapy), Humans, Osteoporosis (drug therapy), Treatment Outcome.
MESH :
- chemical , administration & dosage : Bone Density Conservation Agents, Diphosphonates.
- chemical , adverse effects : Bone Density Conservation Agents, Diphosphonates.
- chemical , pharmacokinetics : Bone Density Conservation Agents, Diphosphonates.
- chemical , therapeutic use : Bone Density Conservation Agents, Diphosphonates.
- drug therapy : Bone Diseases, Fractures, Stress, Osteoporosis.
- Cost-Benefit Analysis, Humans, Treatment Outcome.

Abstract

Bisphosphonates are antiresorptive drugs widely used to treat osteoporosis. They are also used to treat hereditary skeletal diseases with systemic or local defects, and as a supplement in treatment of cancer. This paper provides an overview of pharmacokinetics, mode of action, and clinical effects.

DOI: 10.4045/tidsskr.09.0470
PubMed: 21304573

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Bisphosphonate treatment of osteoporosis and other skeletal diseases].</title>
<author><name sortKey="Syversen, Unni" sort="Syversen, Unni" uniqKey="Syversen U" first="Unni" last="Syversen">Unni Syversen</name>
<affiliation wicri:level="3"><nlm:affiliation>Avdeling for endokrinologi, St. Olavs hospital, Trondheim. unni.syversen@ntnu.no</nlm:affiliation>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
<wicri:orgArea>Avdeling for endokrinologi, St. Olavs hospital</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Halse, Johan I" sort="Halse, Johan I" uniqKey="Halse J" first="Johan I" last="Halse">Johan I. Halse</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21304573</idno>
<idno type="pmid">21304573</idno>
<idno type="doi">10.4045/tidsskr.09.0470</idno>
<idno type="wicri:Area/PubMed/Corpus">000652</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000652</idno>
<idno type="wicri:Area/PubMed/Curation">000650</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000650</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000596</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000596</idno>
<idno type="wicri:Area/Ncbi/Merge">000430</idno>
<idno type="wicri:Area/Ncbi/Curation">000430</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000430</idno>
<idno type="wicri:Area/Main/Merge">001506</idno>
<idno type="wicri:Area/Main/Curation">001504</idno>
<idno type="wicri:Area/Main/Exploration">001504</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Bisphosphonate treatment of osteoporosis and other skeletal diseases].</title>
<author><name sortKey="Syversen, Unni" sort="Syversen, Unni" uniqKey="Syversen U" first="Unni" last="Syversen">Unni Syversen</name>
<affiliation wicri:level="3"><nlm:affiliation>Avdeling for endokrinologi, St. Olavs hospital, Trondheim. unni.syversen@ntnu.no</nlm:affiliation>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
<wicri:orgArea>Avdeling for endokrinologi, St. Olavs hospital</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Halse, Johan I" sort="Halse, Johan I" uniqKey="Halse J" first="Johan I" last="Halse">Johan I. Halse</name>
</author>
</analytic>
<series><title level="j">Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke</title>
<idno type="eISSN">0807-7096</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone Density Conservation Agents (administration & dosage)</term>
<term>Bone Density Conservation Agents (adverse effects)</term>
<term>Bone Density Conservation Agents (pharmacokinetics)</term>
<term>Bone Density Conservation Agents (therapeutic use)</term>
<term>Bone Diseases (drug therapy)</term>
<term>Cost-Benefit Analysis</term>
<term>Diphosphonates (administration & dosage)</term>
<term>Diphosphonates (adverse effects)</term>
<term>Diphosphonates (pharmacokinetics)</term>
<term>Diphosphonates (therapeutic use)</term>
<term>Fractures, Stress (drug therapy)</term>
<term>Humans</term>
<term>Osteoporosis (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents de maintien de la densité osseuse (administration et posologie)</term>
<term>Agents de maintien de la densité osseuse (effets indésirables)</term>
<term>Agents de maintien de la densité osseuse (pharmacocinétique)</term>
<term>Agents de maintien de la densité osseuse (usage thérapeutique)</term>
<term>Analyse coût-bénéfice</term>
<term>Diphosphonates (administration et posologie)</term>
<term>Diphosphonates (effets indésirables)</term>
<term>Diphosphonates (pharmacocinétique)</term>
<term>Diphosphonates (usage thérapeutique)</term>
<term>Fractures de fatigue (traitement médicamenteux)</term>
<term>Humains</term>
<term>Maladies osseuses (traitement médicamenteux)</term>
<term>Ostéoporose (traitement médicamenteux)</term>
<term>Résultat thérapeutique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Diseases</term>
<term>Fractures, Stress</term>
<term>Osteoporosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Fractures de fatigue</term>
<term>Maladies osseuses</term>
<term>Ostéoporose</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term>
<term>Humains</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Bisphosphonates are antiresorptive drugs widely used to treat osteoporosis. They are also used to treat hereditary skeletal diseases with systemic or local defects, and as a supplement in treatment of cancer. This paper provides an overview of pharmacokinetics, mode of action, and clinical effects.</div>
</front>
</TEI>
<affiliations><list><country><li>Norvège</li>
</country>
<region><li>Trøndelag</li>
</region>
<settlement><li>Trondheim</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Halse, Johan I" sort="Halse, Johan I" uniqKey="Halse J" first="Johan I" last="Halse">Johan I. Halse</name>
</noCountry>
<country name="Norvège"><region name="Trøndelag"><name sortKey="Syversen, Unni" sort="Syversen, Unni" uniqKey="Syversen U" first="Unni" last="Syversen">Unni Syversen</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001504 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001504 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21304573
   |texte=   [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21304573" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021

Serveur d'exploration Stress et Covid

[Bisphosphonate treatment of osteoporosis and other skeletal diseases].

[Bisphosphonate treatment of osteoporosis and other skeletal diseases].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Stress et Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.